“Efficacy of the Pfizer-Biontech vaccine (BNT162b1) for prevention of SARS-CoV-2 in Adult Participants currently being studied. Currently, efficacy is unknown – there is no recognized effective vaccine for the treatment of COVID-19. Estimated Study Completion Date: January 31, 2023”

BioNTech SE. Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates against COVID-19 in Healthy Individuals. Clinicaltrials.gov, U.S. National Library of Medicine, Retrieved 2 April 2021. https://clinicaltrials.gov/ct2/show/NCT04368728.